USFDA has released a new set of guidelines for the use of already approved Recombinant Human Papillomavirus 9-valent Vaccine (GARDASIL 9) in males.
New HPV Vaccine, Gardasil 9 by Merck, is More Effective
A new vaccine against sexually transmitted human papillomavirus (HPV), Gardasil 9 made by Merck, is more effective than the previous version.
A new vaccine against sexually transmitted human papillomavirus (HPV), Gardasil 9 made by Merck, is more effective than the previous version.
‘GARDASIL 9, Merck’s Human Papilloma Vaccine can now be administered to males from 16 through 26 years of age to prevent oral cancer, precancerous lesions and genital warts.’
The vaccine prevents oral cancer caused by HPV types (16, 18, 31, 33, 45, 52 and 58), precancerous or dysplastic lesions caused by HPV types (6, 11, 16, 18, 31, 33, 45, 52 and 58) and genital warts caused by HPV types 6 and 11. GARDASIL 9 has been already approved by the USFDA for use in boys 9 through 15 years of age for the prevention of these diseases. Similarly, the vaccine can prevent cervical, vulvar, vaginal, and anal cancers caused by HPV types when administered to girls and young women 9 through 26 years of age.
GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant].
HPV Vaccine Does Not Cause Riskier Sexual Practices, STIs
Despite concerns among some parents, the vaccine against human papillomavirus (HPV) does not cause riskier behavior in teens, nor does it raise rates of sexually transmitted infections.
Despite concerns among some parents, the vaccine against human papillomavirus (HPV) does not cause riskier behavior in teens, nor does it raise rates of sexually transmitted infections.
Free HPV Vaccine Reduces Number of Genital Warts
Cases of genital warts among young women has reduced by 61 percent in Australia since the introduction of the national human papillomavirus (HPV) vaccination program.
Cases of genital warts among young women has reduced by 61 percent in Australia since the introduction of the national human papillomavirus (HPV) vaccination program.
HPV Vaccination is Associated With Reduced Cervical Lesions Risk
Among Danish girls and women a reduced risk of cervical lesions is associated with use of a quadrivalent HPV vaccine, says research published in the Journal of the National Cancer Institute.
Among Danish girls and women a reduced risk of cervical lesions is associated with use of a quadrivalent HPV vaccine, says research published in the Journal of the National Cancer Institute.
